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Objective. To obtain a real-world perspective of the optimal timing of angiography performed within 24 hours of admission with non-ST
elevation myocardial infarction (NSTEMI). Background. Current guidelines recommend angiography within 24 hours of hospitalisation
with NSTEMI. *e recent VERDICT trial found that angiography within 12 hours of admission with NSTEMI was associated with
improved cardiovascular outcomes among high-risk patients. We compared the outcomes of real-world NSTEMI patients undergoing
angiography within 12 hours of admission with those of patients undergoing angiography 12 to 24 hours after admission. Methods.
NSTEMI patients without life-threatening features who received angiography within 24 hours of admission were obtained from the
SPUM-ACS registry, a cohort of consecutive patients admitted with acute coronary syndromes to four university hospitals in Switzerland.
Cox models assessed for an association between door-to-catheter time and one-year major adverse cardiovascular events (MACE:
cardiovascular mortality, myocardial infarction, and stroke). Results. Of 2672 NSTEMI patients, 1832 met the inclusion criteria. Among
them, 1464 patients underwent angiography within 12 hours (12h group) compared with 368 patients between 12 and 24 hours (12–24h
group). Multiple logistic regression identified out-of-hours admission as the only factor associated with delayed angiography. After 2 :1
propensity score matching, 736 patients from the 12h group and 368 patients from the 12–24h group demonstrated no significant
difference in rates of one-yearMACE (7.7% vs. 7.3%, HR:1.050, 95%CI 0.637–1.733,p � 0.847). Stratification byGRACE score (>140 vs.≤140) found no significant reduction inMACE among high-risk patients in the 12h group (p for interaction� 0.601). Conclusions. In an
unselected real-world cohort of NSTEMI patients, angiography within 12 hours of admission was not associated with improved one-year
cardiovascular outcomes when compared with angiography 12 and 24 hours after admission, even among high-risk patients.
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1. Introduction
Current European and American guidelines recommend
angiography within 24 hours of hospitalisation for patients
with non-STelevationmyocardial infarction (NSTEMI). Key
to these recommendations was the TIMACS trial (Timing of
Intervention in Acute Coronary Syndromes) which found
that invasive angiography within 24 hours of admission was
associated with a reduced rate of recurrent ischemia at
6 months when compared with angiography ≥36 hours after
admission [1]. Additionally, a reduced rate of the composite
primary endpoint (death, myocardial infarction (MI), and
stroke) was noted among patients with a GRACE score >140
receiving early angiography. Further support came from the
RIDDLE-NSTEMI trial, which found that early angiography
(median time 1.4 hours) following NSTEMI was associated
with reduced mortality/recurrent MI at both 30 days and
1 year when compared with a delayed strategy (median
time 61 hours) [2]. Meta-analyses have provided additional
support for these recommendations [3,4]. Of note, Jobs et al.
analysed data from eight studies (including TIMACS and
RIDDLE-NSTEMI) and found reduced 6-month mortality
among NSTEMI patients treated with an early invasive
strategy [4].
*e recent VERDICT (Very EaRly vs Deferred Invasive
evaluation using Computerized Tomography) trial provided
evidence of the potential benefits of even earlier intervention
in high-risk patients. Patients without life-threatening features
were randomised to receive angiography within 12 hours or
between 48 and 72 hours. Among the early intervention group,
patients with a GRACE score >140 were found to have a
reduced rate of the primary composite endpoint (all-cause
death, nonfatal recurrent MI, admission for refractory myo-
cardial ischemia, or heart failure) at 4 years [5]. However, there
are limitations in the design of the VERDICT trial that po-
tentially reduce its applicability to clinical practice. Firstly, early
angiography was delivered with a median door-to-catheter
(DTC) time of 4.7 hours (IQR 3.0–12.2), compared to a
delayed strategy with a median DTC time of 61.6 hours
(IQR 39.4–87.8). *is represents a substantial treatment
delay that high-risk patients typically would not experience
in routine clinical practice. Secondly, DTC times between
12 and 24 hours were not considered despite a significant
proportion of patients in clinical practice likely experi-
encing a delay of this length.
*e sheer volume of NSTEMI admissions makes the
timely delivery of angiography a significant challenge for
clinicians and the latest evidence from the VERDICT trial
could be interpreted as supporting an even more challenging
angiography target in high-risk NSTEMI.
We aimed to obtain a real-world perspective of the
optimal timing of invasive angiography following NSTEMI
among patients treated within the recommended 24-hour
target. In a retrospective analysis of consecutive pa-
tients admitted with NSTEMI to four university hospitals
across Switzerland, we compared one-year outcomes
of patients receiving angiography within 12 hours with
those of patients receiving angiography between 12 and
24 hours.
2. Materials and Methods
2.1.Patients. Datawere obtained from the SPUM-ACS (Special
Program University Medicine–Acute Coronary Syndromes)
registry, a cohort of consecutive patients admitted with acute
coronary syndromes (ACS) to four PCI-capable university
hospitals in Switzerland. ACS was defined as the presence of
symptoms consistent with angina pectoris and at least one of
the following characteristics: ST-segment elevation or de-
pression, T inversion or dynamic ECG changes, evidence of
positive troponin, and/or known coronary heart disease
(status after myocardial infarction, bypass surgery,
or coronary angiography). All patients were aged 18 years or
over with the only exclusion criteria being severe physical
disability, inability to comprehend the study, or life expectancy
of less than 1 year (for noncardiac reasons). Further details of
this registry have been reported previously [6]. For the present
study, patients hospitalised between 2009 and 2017 with a
diagnosis of NSTEMI were selected. NSTEMI was defined as
elevated troponin levels and the absence of ST elevation at
the time of diagnosis. Among them, DTC time was calcu-
lated by subtracting the time of coronary catheter insertion
from the time of hospitalisation. Patients without a DTC
time, those receiving angiography greater than 24 hours after
admission, and those presenting with very-high-risk criteria
(cardiac arrest, systolic blood pressure< 90mmHg, acute
cardiac failure (Killip class III or IV), and ST elevation on
ECG) were excluded.
2.2. Primary Endpoint. *e primary endpoint was defined
as one-year major adverse cardiovascular events
(MACE), a composite of cardiovascular mortality, re-
current MI (using the universal definition of MI [7]), and
stroke. *e incidence of cardiovascular events during
follow-up was ascertained by telephone consultation 30
days after discharge and in a clinical face-to-face visit at
one year. When patients could not be reached for the one-
year follow-up visit, medical information was obtained
from primary care physicians, family members, hospital
records, or a registry office. *ree certified cardiologists
adjudicated all cardiovascular events.
2.3. Statistical Analysis. Normally distributed, continuous
variables are expressed as mean± SD and compared using
the 2-tailed Student t-test. Nonnormally distributed contin-
uous variables are expressed as a median with interquartile
range and analysed using the Mann–Whitney U test. Com-
parisons between categorical variables were performed using
the Pearson χ2 test. Missing values in baseline clinical
characteristics were treated with multiple imputation in
order to create five imputed datasets. Baseline and treat-
ment characteristics are presented for a single imputed
dataset. Logistic and Cox regression analyses were performed
on each imputed dataset before pooling of estimates as per
Rubin’s Rules [8]. Multiple logistic regression was used to
identify independent factors associated with an angiography
delay of 12–24 hours. *ese models included the following
covariates: age, sex, hypertension, diabetes, previous
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cardiovascular disease, chronic lung disease, smoking status,
heart rate, systolic blood pressure, ECG ischemia, anaemia,
estimated glomerular filtration rate (eGFR), GRACE score,
admission at night, and admission on weekend. A 2 :1 pro-
pensity score-matched analysis with a nearest-neighbour
matching algorithmwas used tomanage differences in baseline
characteristics. Patients were matched for age, sex, diabetes,
hypertension, hypercholesterolemia, previous MI, previous
PCI, previous CABG, previous stroke, previous CVD, valvular
disease, chronic lung disease, family history of CVD, systolic
blood pressure, heart rate, BMI, anaemia, baseline eGFR, ECG
ischemia, smoking, GRACE score, and LVEF. Cox propor-
tional hazardsmodels assessed for an association betweenDTC
time and the clinical endpoints. Stratified Kaplan–Meier
analysis was used to visualise intergroup differences for each
clinical outcome over the follow-up period. A p-value <0.05
was defined as statistically significant. Statistical analysis was
performed using R version 3.5.1.
3. Results
3.1. Patients. Of 2672 NSTEMI patients, 534 without a DTC
time and 94 with a DTC time greater than 24 hours were
excluded. A further 212 patients were excluded due to
presence of very-high-risk criteria. Among the remaining
1832 eligible patients, 1464 patients received angiography
within 12 hours of admission (12 h group) while 368 patients
received angiography between 12 and 24 hours (12–24 h
group). Missing values in baseline clinical characteristics
were managed with multiple imputation (Supplementary
Table 1). Prior to matching, the groups differed significantly
with regards to age, previous cardiovascular disease, and baseline
eGFR. After 2 :1 propensity score matching, 736 patients from
the 12 h group and 368 patients from the 12–24 h group
presented no significant differences in main baseline clinical
characteristics (Table 1). *e median follow-up time was
365.2 days (IQR 358.0–365.2) in both the 12 h and 12–24 h
Table 1: Baseline characteristics of unmatched and matched populations. Propensity score 2 :1 matching performed using a nearest
neighbour matching algorithm.
Baseline characteristics
Unmatched Matched<12 h (n� 1464) 12–24 h(n� 368) p-value <12 h (n� 736) 12–24 h(n� 368) p-value
Age, median (IQR) 63.05 (54.10,72.40)
64.65 (55.88,
75.10) 0.015
65.00 (56.00,
75.00)
64.65 (55.88,
75.10) 0.853
Female (%) 308 (21.0) 91 (24.7) 0.144 178 (24.2) 91 (24.7) 0.901
Hypertension (%) 883 (60.4) 225 (61.1) 0.840 465 (63.2) 225 (61.1) 0.553
Diabetes (%) 286 (19.5) 63 (17.1) 0.324 120 (16.3) 63 (17.1) 0.797
Hypercholesterolemia (%) 980 (67.1) 234 (63.6) 0.228 476 (64.7) 234 (63.6) 0.773
Previous MI (%) 209 (14.3) 65 (17.7) 0.119 149 (20.2) 66 (17.9) 0.405
Previous PCI (%) 231 (15.8) 71 (19.4) 0.113 159 (21.6) 73 (19.8) 0.548
Previous CABG (%) 79 (5.4) 28 (7.6) 0.136 60 (8.2) 28 (7.6) 0.844
Previous stroke (%) 34 (2.3) 12 (3.3) 0.401 28 (3.8) 12 (3.3) 0.776
Previous CVD (%) 370 (25.3) 118 (32.1) 0.010 245 (33.3) 118 (32.1) 0.734
Valvular disease (%) 27 (1.8) 5 (1.4) 0.678 11 (1.5) 5 (1.4) 1.000
Chronic lung disease (%) 67 (4.6) 18 (4.9) 0.912 34 (4.6) 18 (4.9) 0.960
Family history of CAD (%) 397 (27.4) 97 (26.4) 0.759 173 (23.5) 97 (26.4) 0.334
Smoking (%) 562 (38.4) 125 (34.0) 0.132 243 (33.0) 125 (34.0) 0.804
BMI (kg/m2) 27.43 (4.44) 27.08 (4.73) 0.191 27.14 (4.33) 27.07 (4.72) 0.814
Haemoglobin (g/l),
mean (SD) 137.11 (18.17) 136.28 (18.27) 0.445 136.56 (17.61) 136.24 (18.10) 0.777
Anemia (%) 305 (21.9) 82 (23.4) 0.577 159 (21.6) 88 (23.9) 0.429
Haematocrit, mean (SD) 40.36 (5.06) 40.28 (5.18) 0.787 40.26 (4.88) 40.26 (5.13) 0.990
eGFR, mean (SD) 92.75 (27.33) 89.18 (27.17) 0.026 89.65 (27.16) 89.22 (27.21) 0.804
LVEF, mean (SD) 55.41 (10.12) 55.92 (10.30) 0.407 55.66 (10.40) 55.88 (10.37) 0.733
ECG ischemia (%) 864 (62.0) 208 (58.3) 0.215 445 (60.5) 211 (57.3) 0.351
Heart rate (beats per minute), mean (SD) 75.33 (14.65) 76.40 (15.23) 0.215 75.94 (14.83) 76.40 (15.23) 0.634
Systolic blood pressure (mmHg), mean
(SD) 132.78 (22.26) 133.02 (21.64) 0.851 133.08 (21.96) 132.88 (21.63) 0.885
GRACE score, mean (SD) 126.68 (27.85) 129.41 (29.15) 0.099 130.12 (27.84) 129.21 (29.07) 0.611
GRACE score >140 (%) 437 (30.8) 131 (36.0) 0.068 258 (36.4) 131 (36.0) 0.951
Killip class 2 (%) 90 (6.3) 26 (7.2) 0.626 45 (6.2) 26 (7.2) 0.658
Door-to-catheter time in minutes, median
(IQR) 3.50 (1.80, 6.10)
16.80 (14.40,
19.50) <0.001 3.50 (1.80, 6.00)
16.80 (14.40,
19.50) <0.001
BMI� body mass index; CABG� coronary artery bypass graft; CAD� coronary artery disease; CVD� cardiovascular disease; eGFR� estimated glomerular
filtration rate; GRACE�Global Registry of Acute Coronary Events; IQR� interquartile range; LVEF� left ventricular ejection fraction; MI�myocardial
infarction; PCI� percutaneous intervention; SD� standard deviation.
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groups.*emedian DTC time was 3.5 hours (IQR 1.8–6.0) in
the 12 h group and 16.8 hours (IQR 14.4–19.5) in the 12–24 h
group. *e mean GRACE score was 130.12 (SD 27.84) in the
12 h group and 129.21 (SD 29.07) in the 12–24 h group. In
both groups, 36% of patients had a GRACE score over 140.
With regards to treatment, both groups in the matched
population had over 99% compliance with dual antiplatelet
therapy at the time of discharge, though a smaller proportion of
patients in the 12–24h group were prescribed prasugrel
(Table 2). *ere was also a higher incidence of coronary
thrombus in the early intervention group (21.1% vs.
13.2%,p � 0.003). However, there were no other significant
differences in treatment characteristics. Of note, there were no
significant differences in the proportion of patients receiving
stenting (12h: 84.8% vs. 12–24h: 82.3%), balloon angioplasty
only (12h: 5.0% vs. 12–24h: 5.4%), or CABG following angi-
ography (12h: 1.9% vs. 12–24h: 1.6%) (p � 0.606). As reported
previously, there was strong adherence to ACS prescription
guidelines [6].
3.2. Factors Associated with Angiography Delays of 12–24
Hours. Within the 12–24h group, a much higher proportion
of admissions occurred on weekday nights (12 h: 18.2% vs.
Table 2: Treatment summary.
Treatment characteristics
Unmatched Matched<12 h (n� 1464) 12–24 h (n� 368) p-value <12 h (n� 736) 12–24 h (n� 368) p-value
Angiography
Revascularisation (%) 0.227 0.606
PCI—implantation of stent(s) 1246 (85.2) 302 (82.3) 624 (84.8) 302 (82.3)
PCI—balloon dilatation only 69 (4.7) 20 (5.4) 37 (5.0) 20 (5.4)
CABG 35 (2.4) 6 (1.6) 14 (1.9) 6 (1.6)
No revascularisation 113 (7.7) 39 (10.6) 61 (8.3) 39 (10.6)
AHA lesion class—worst (%) 0.781 0.742
1 344 (25.6) 88 (27.2) 166 (24.8) 88 (27.2)
2 602 (44.9) 147 (45.4) 301 (44.9) 147 (45.4)
3 203 (15.1) 42 (13.0) 101 (15.1) 42 (13.0)
4 193 (14.4) 47 (14.5) 102 (15.2) 47 (14.5)
Stent number (%) 0.112 0.214
0 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.3)
1 1012 (81.2) 238 (79.1) 508 (81.4) 238 (79.1)
2 193 (15.5) 51 (16.9) 103 (16.5) 51 (16.9)
3 32 (2.6) 7 (2.3) 10 (1.6) 7 (2.3)
4 8 (0.6) 2 (0.7) 3 (0.5) 2 (0.7)
5 1 (0.1) 2 (0.7) 0 (0.0) 2 (0.7)
TIMI flow post-PCI (%) 0.808 0.829
0 11 (0.8) 2 (0.6) 6 (0.9) 2 (0.6)
1 6 (0.5) 1 (0.3) 3 (0.5) 1 (0.3)
2 20 (1.5) 7 (2.2) 10 (1.5) 7 (2.2)
3 1283 (97.2) 310 (96.9) 643 (97.1) 310 (96.9)
*rombus (%) 305 (22.6) 43 (13.2) <0.001 142 (21.1) 43 (13.2) 0.003
Aspiration (%) 193 (64.3) 25 (59.5) 0.663 87 (62.1) 25 (59.5) 0.900
Discharge medications
Aspirin (%) 1444 (99.2) 362 (99.5) 0.841 725 (99.5) 362 (99.5) 1.000
Beta-blocker (%) 1175 (80.8) 295 (81.0) 0.979 600 (82.4) 295 (81.0) 0.636
ACE inhibitor (%) 1022 (70.3) 252 (69.2) 0.741 503 (69.1) 252 (69.2) 1.000
ARB (%) 260 (17.9) 70 (19.2) 0.602 143 (19.6) 70 (19.2) 0.935
Statin (%) 1445 (99.3) 358 (98.4) 0.149 723 (99.3) 358 (98.4) 0.239
P2Y12 agent (%) <0.001 0.011
Clopidogrel 616 (44.4) 178 (52.2) 339 (48.4) 178 (52.2)
Prasugrel 235 (17.0) 29 (8.5) 106 (15.1) 29 (8.5)
Ticagrelor 535 (38.6) 134 (39.3) 255 (36.4) 134 (39.3)
Admission timing
Admission time (%) <0.001 <0.001
Weekday (day) 936 (63.9) 112 (30.4) 488 (66.3) 112 (30.4)
Weekday (night) 288 (19.7) 163 (44.3) 134 (18.2) 163 (44.3)
Weekend 240 (16.4) 93 (25.3) 114 (15.5) 93 (25.3)
Time of day, median (IQR) 10 :19(07 : 46–13 : 53)
18 : 02
(14 :10–20 : 40) <0.001
10 : 21
(07 : 55–13 : 52)
18 : 02
(14 :10–20 : 40) <0.001
Length of hospital stay in days,
median (IQR) 2.12 (1.00, 4.51) 3.00 (1.16, 5.00) 0.001 2.00 (1.00, 4.39) 3.00 (1.16, 5.00) 0.001
ACE� angiotensin-converting enzyme; AHA�American Heart Association; ARB� angiotensin receptor blocker; CABG� coronary artery bypass graft;
IQR� interquartile range; PCI� percutaneous intervention; SD� standard deviation; TIMI� thrombolysis in myocardial infarction.
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12–24h: 44.3%) and on weekends (12h: 15.5% vs. 12–24 h:
25.3%) (Table 2). *is finding was reflected in the timing of
admissions, with patients in the 12 h group typically admitted
in the morning (median time 10 : 21, IQR 07 : 55–13 : 52),
compared with much later admissions in the 12–24 h group
(median time 18 : 02, IQR 14 :10–20 : 40). After adjustment for
a range of baseline characteristics including age, past medical
conditions, and GRACE score, logistic regression identified
admission at night (OR 4.462, 95% CI 3.221–6.181, p< 0.001)
or on weekends (OR 1.503, 95% CI 1.031–2.191, p � 0.032) as
the only significant factors associated with an angiography delay
of 12–24 hours. On average, patients in the 12–24h group
remained in hospital for one day longer than those in the 12 h
group (12 h: median 2.0 days, IQR 1.0–4.4 vs. 12–24 h:
median 3.0 days, IQR 1.2–5.0, p< 0.001).
3.3. Outcomes inOverall Population. At one year, the primary
endpoint (MACE) occurred in 7.7% of patients in the 12h
group compared with 7.3% of patients in the 12–24h group
(HR: 1.050, 95% CI 0.637–1.733, p � 0.847). *ere was in-
creased cardiovascularmortality in the 12–24h group; however,
this was not statistically significant (1.8% vs. 2.7%, HR: 1.767,
95% CI 0.712–4.387, p � 0.219). Additionally, there were no
significant differences between groups with regards to
recurrent MI (6.1% vs. 6.0%, HR: 1.095, 95% CI
0.613–1.953,p � 0.758) or stroke (1.8% vs. 1.6%, HR: 0.993,
95% CI 0.359–2.747, p � 0.989) (Figure 1). *ese findings
were corroborated with Kaplan–Meier analyses which dem-
onstrated no significant differences between groups with regards
to MACE (p � 0.82), cardiovascular mortality (p � 0.23), re-
current MI (p � 0.88), or stroke (p � 0.72) at one year
(Figure 2).
3.4. Outcomes in High-Risk Patients. Among patients with a
GRACE score >140 (12 h: 36.4% vs. 12–24 h: 36.0%), there
was no significant difference between groups with regards
to the rate of MACE (10.7% vs. 11.5%, HR: 1.189, 95% CI
0.611–2.316, p for interaction� 0.601). *ere was increased
cardiovascular mortality (3.7% vs. 6.1%, HR: 1.895, 95% CI
0.640–5.613) in the 12–24 h group; however, this difference
was not statistically significant (p for interaction� 0.778).
*e rates of recurrent MI (7.8% vs. 9.2%, HR: 1.323, 95% CI
0.605–2.891) and stroke (3.0% vs. 3.1%, HR: 1.142, 95% CI
0.310–4.211) were also not significantly different in the 12 h
and 12–24 h groups at one year (p for interaction� 0.494
and 0.740, respectively) (Figure 1). *is absence of benefit
among patients with a GRACE score >140 was confirmed
with KM analyses for all clinical endpoints (Figure 3).
Endpoint (one-year)
MACE
Overall
GRACE score
≤140
>140
Cardiovascular mortality
Overall
GRACE score
≤140
>140
Recurrent MI
Overall
GRACE score
≤140
>140
Stroke
Overall
GRACE score
≤140
>140
<12 hours
events (%)
57 (7.7)
28 (6.0)
29 (10.7)
13 (1.8)
3 (0.6)
10 (3.7)
45 (6.1)
24 (5.2)
21 (7.8)
13 (1.8)
5 (1.1)
8 (3.0)
12−24 hours
events (%)
27 (7.3)
12 (5.1)
15 (11.5)
10 (2.7)
2 (0.8)
8 (6.1)
22 (6.0)
10 (4.2)
12 (9.2)
6 (1.6)
2 (0.8)
4 (3.1)
Hazard ratio
(95% CI)
1.050 (0.637-1.733)
0.916 (0.442-1.896)
1.189 (0.611-2.316)
1.767 (0.712-4.387)
1.381 (0.210-9.065)
1.895 (0.640-5.613)
1.095 (0.613-1.953)
0.907 (0.407-2.020)
1.323 (0.605-2.891)
0.993 (0.359-2.747)
0.794 (0.146-4.312)
1.142 (0.310-4.211)
p-value
0.847
0.813
0.610
0.219
0.736
0.246
0.758
0.811
0.482
0.989
0.789
0.842
p-value for
interaction
0.601
0.778
0.494
0.740
0.12 0.25 0.50 1.0 2.0 4.0 8.0
12−24 h better <12 h better
Figure 1: Forest plot of one-year endpoints in the overall matched population and after stratification by GRACE score. MACE represents a
composite of cardiovascular mortality, recurrent MI, and stroke. For each one-year clinical endpoint, event rates are presented for the <12 h
and 12–24 h groups along with the hazard ratio and p-value from the corresponding Cox proportional hazards model. For the GRACE score
subgroup analysis, the p-value for interaction is presented. CI� confidence interval; GRACE�Global Registry of Acute Coronary Events;
MACE�major adverse cardiovascular events; MI�myocardial infarction.
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4. Discussion
*is study demonstrates that in a matched cohort of NSTEMI
patients without life-threatening features, patients receiving
invasive angiography within 12 hours had similar one-year
cardiovascular outcomes to those treated between 12 and
24 hours. *is finding was independent of GRACE score,
with high-risk patients (GRACE score >140) having similar
outcomes in both the 12 h and 12–24 h groups.
4.1. Relevance to Routine Clinical Practice. *e VERDICT
trial was key to the conception of this study. It demonstrated
that angiography within 12 hours was only associated with
improved long-term outcomes among non-ST elevation
acute coronary syndrome (NSTE-ACS) patients with a
GRACE score >140 [5]. However, direct comparison of our
results with those of the VERDICT trial should be limited
due to an important difference between the delayed inter-
vention groups. In the VERDICT trial, early angiography
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Figure 2: Kaplan–Meier plots stratified by door-to-catheter time for one-year endpoints. MACE represents a composite of cardiovascular
mortality, recurrent MI, and stroke. For each endpoint, the p-value from the corresponding log-rank test is presented. MACE�major
adverse cardiovascular events; MI�myocardial infarction.
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was compared with delayed angiography conducted between
48 and 72 hours (median DTC time 61.6 hours, IQR
39.4–87.8). In routine clinical practice, high-risk NSTE-ACS
patients typically do not experience such long delays,
with current guidelines recommending angiography within
24 hours [9, 10]. *us, this key finding from the VERDICT
trial should not come as a surprise. However, our study
addresses a gap in the VERDICT trial design by assessing the
impact of delays experienced within the recommended
24-hour window. It is not uncommon for patients
hospitalised with NSTEMI to experience delays prior to
angiography [11, 12]. In this study, admission out-of-hours
was the factor most strongly associated with delays of greater
than 12 hours. Importantly, our data suggest that these delays
do not have a significant association with one-year cardio-
vascular outcomes, provided that angiography is performed
within the guideline-recommended 24-hour timeframe.
Support for these findings come from the TIMACS trial
which noted no significant difference in 6-month outcomes
between patients treated within 6 hours, 6 to 12 hours or
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12 to 24 hours [1]. Additionally, post-hoc analysis of the
ACUITY trial (Acute Catheterization and Urgent Interven-
tion Triage strategY) found no significant difference in
30-day or one-year outcomes between patients treated
within 8 hours or between 8 and 24 hours [13].
It should be noted that the event rates in this study were
lower than reported in previous studies, whichmay reflect an
overall lower-risk NSTEMI population. For example, this
study excluded patients presenting with any life-threatening
features (as per European/American guidelines), whereas
trials such as TIMACS and ACUITY included many of these
patients [1, 13]. Additionally, compared with the present
study, the VERDICT trial included patients with a higher-
mean GRACE score (141 vs. 130) and a higher percentage
of GRACE scores >140 (49% vs. 36%), suggesting an overall
higher-risk population [5].*e presence of a lower-risk NSTEMI
population in the present studymay help explain why the referral
rate for CABG was lower than reported in other studies.
4.2. Benefits of Early versus Delayed Angiography. *e the-
oretical benefit of early angiography is the early identification
of significant lesions facilitating early revascularisation and
salvage of ischemic myocardium. Additionally, early angi-
ography can promote early discharge. In this study, patients
in the 12–24 h group had significantly longer hospital stays
likely reflecting the delay in receiving angiography. On the
other hand, delayed angiography following NSTEMI may
provide adequate time for optimal medical treatment in
order to decrease thrombus burden, improve plaque sta-
bility, and reduce subsequent stent thrombosis risk. *e
presence of coronary thrombus at the time of angiography
is known to worsen outcomes following ACS [14]. Fur-
thermore, in vitro models have shown that P2Y12 agents can
disrupt and even reverse thrombus stability [15, 16]. Longer
pretreatment with P2Y12 agents is also associated with
improved coronary perfusion before PCI [17]. In this study,
the proportion of patients with coronary thrombus was
significantly higher in the early intervention group. *us, it
could be hypothesised that angiography deferred to between
12 and 24 hours may have provided time for the beneficial
effects of medical therapy to be seen.
4.3. Limitations. *is study is limited by its retrospective
and observational design. As it is not possible to exclude
the possibility of selection bias, these results should be
considered as hypothesis generating. However, the SPUM-
ACS registry represents a multicentre cohort of consec-
utive patients hospitalised with ACS. Additionally, given
the very few exclusion criteria, we feel that the risk of bias
is limited and that patients included in this study are likely
representative of those encountered in routine clinical
practice. Another limitation was the modestly-sized, im-
balanced groups. To counter this, we applied 2 : 1 pro-
pensity score matching to create statistically balanced
groups for comparison. However, it is possible that the
small sample sizes in this study may have reduced the
chance of detecting significant intergroup differences,
particularly in the stratified GRACE score analysis. *ere
was a higher rate of one-year cardiovascular mortality
among patients receiving angiography between 12 and 24
hours, albeit nonsignificant. Interpretation of this compo-
nent of the composite endpoint should be performed with
caution given the small sample size. A further limitation is
that the definition of MI changed during the study period
(2009–2017), and thus a degree of heterogeneity could be
present in the population. *ere were also relatively low
prescription rates of ticagrelor and prasugrel in this study.
*is was likely reflective of the long study period which
encompassed a shift in practice from higher rates of clo-
pidogrel use at the start of the study period towards higher
rates of more potent P2Y12 agents by the end of the study. A
further limitation was the absence of detailed information on
coronary thrombosis. A higher rate of coronary thrombosis
was detected among patients in the 12h; however, no infor-
mation was available on thrombosis of preexisting coronary
stents. Finally, with a median follow-up period of 365 days,
this study cannot exclude the possibility of differences in
outcomes beyond this timepoint.
5. Conclusion
In this real-world cohort of NSTEMI patients, angiography
within 12 hours of hospitalisation was not associated with
improved one-year cardiovascular outcomes when com-
pared with angiography between 12 and 24 hours, even
among patients with an elevated GRACE score.
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